Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 688 results
Found 688 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  


Hennig S, Svensson EM, Niebecker R, et al. "Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs." J. Antimicrob. Chemother.. 2016;71(5):1330-40.
Hennig S, Naiker S, Reddy T, et al. "Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis." Antimicrob. Agents Chemother.. 2015;60(1):617-20.
Henrich TJ, Tsibris AMN, Lewine NRP, et al. "Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate." J. Acquir. Immune Defic. Syndr.. 2010;55(4):420-7.
Henrich TJ, Ribaudo HJ, Kuritzkes DR. "Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy." Clin. Infect. Dis.. 2010;51(1):93-8.
Henrich TJ, Hanhauser E, Harrison LJ, et al. "CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy." J. Infect. Dis.. 2016;213(5):766-70.
Henrich TJ, McLaren PJ, Rao SSP, et al. "Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study." Open Forum Infect Dis. 2014;1(1):ofu018.
Henrich TJ, Lewine NRP, Lee S-H, et al. "Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists." Antimicrob. Agents Chemother.. 2012;56(4):1931-5.
Henry K, Katzenstein D, Cherng DWeng, et al. "A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102." J. Acquir. Immune Defic. Syndr.. 2006;42(2):140-8.
Hermes A, Squires K, Fredrick L, et al. "Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women." HIV Clin Trials. 2012;13(6):308-23.
Hitti J, Andersen J, McComsey G, et al. "Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084." Am. J. Obstet. Gynecol.. 2007;196(4):331.e1-7.
Hitti J, Halvas EK, Zheng L, et al. "Frequency of Antiretroviral Resistance Mutations among Infants Exposed to Single-Dose Nevirapine and Short Course Maternal Antiretroviral Regimens: ACTG A5207." J AIDS Clin Res. 2014;5(11).
Hochreiter J, Lapham J, Wong-Staal F, et al. "ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection." Antivir. Ther. (Lond.). 2013;18(3):329-36.
Hoffman RM, Jamieson BD, Bosch RJ, et al. "Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals." J. Clin. Immunol.. 2011;31(5):873-81.
Hogan CM, Degruttola V, Sun X, et al. "The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals." J. Infect. Dis.. 2012;205(1):87-96.
Holzinger ER, Grady B, Ritchie MD, et al. "Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants." Pharmacogenet. Genomics. 2012;22(12):858-67.
Hosoya N, Su Z, Wilkin T, et al. "Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions." J. Clin. Microbiol.. 2009;47(8):2604-6.
Hosseinipour MC, Kang M, Krown SE, et al. "As-Needed versus Immediate Etoposide Chemotherapy in Combination with Antiretroviral Therapy for Mild or Moderate AIDS-associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial." Clin. Infect. Dis.. 2018.
Hosseinipour MC, Bisson GP, Miyahara S, et al. "Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial." Lancet. 2016;387(10024):1198-209.
Hu Z, Kuritzkes DR. "Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness." J. Acquir. Immune Defic. Syndr.. 2010;55(2):148-55.
Hu Z, Kuritzkes DR. "Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1." J. Virol.. 2011;85(21):11309-14.
Hu Z, Hatano H, Hammond SP, et al. "Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase." J. Acquir. Immune Defic. Syndr.. 2007;45(5):494-500.
X Hu J, Lagakos SW. "Nonparametric estimation of the mean function of a stochastic process with missing observations." Lifetime Data Anal. 2007;13(1):51-73.
Hua L, Andersen JW, Daar ES, Glesby MJ, Hollabaugh K, Tierney C. "Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment." AIDS. 2013;27(17):2725-34.
Huang JS, Hughes MD, Riddler SA, Haubrich RH. "Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142." HIV Clin Trials. 2013;14(5):224-34.
Huang X-L, Fan Z, Borowski L, Rinaldo CR. "Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8(+) T cell immunity." J. Leukoc. Biol.. 2008;83(6):1530-40.
Huang Y, Liu D, Wu H. "Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system." Biometrics. 2006;62(2):413-23.
Hubbard JJ, Greenwell-Wild T, Barrett L, et al. "Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a." J. Infect. Dis.. 2012;205(9):1443-7.
Hughes MD, Williams PL. "Challenges in using observational studies to evaluate adverse effects of treatment." N. Engl. J. Med.. 2007;356(17):1705-7.
Hulgan T, Robbins GK, Kalams SA, et al. "T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384." PLoS ONE. 2012;7(8):e43803.
Hulgan T, Stein JH, Cotter BR, et al. "Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation." AIDS Res. Hum. Retroviruses. 2013;29(10):1293-9.